JPMA Guidelines: Public Release Of Doctors Lecture Fees Desired
This article was originally published in PharmAsia News
According to transparency guidelines released by the Japan Pharmaceutical Manufacturers Association, lecture and manuscript fees paid by pharmaceutical companies to individual doctors should be published not only on company websites but also in locations specified by each company.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.